154 related articles for article (PubMed ID: 9890546)
1. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Sims EC; Rogers PB; Besser GM; Plowman PN
Clin Oncol (R Coll Radiol); 1998; 10(6):407-9. PubMed ID: 9890546
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
Cömlekçi A; Biberoglu S; Hekimsoy Z; Okan I; Pişkin O; Sekeroglu B; Alakavuklar M
Intern Med; 1998 Apr; 37(4):396-7. PubMed ID: 9630201
[TBL] [Abstract][Full Text] [Related]
3. Metabolic disturbances after a single dose of 30 mg pamidronate for leukaemia-associated hypercalcaemia in a 11-year-old boy.
De Schepper J; de Pont S; Smitz J; De Coster D; Schots R; Otten J
Eur J Pediatr; 1999 Sep; 158(9):765-6. PubMed ID: 10485313
[No Abstract] [Full Text] [Related]
4. Bisphosphonates for metastatic bone pain.
Body JJ
Support Care Cancer; 1999 Jan; 7(1):1-3. PubMed ID: 9926966
[No Abstract] [Full Text] [Related]
5. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports.
Champallou C; Basuyau JP; Veyret C; Chinet P; Debled M; Chevrier A; Grongnet MH; Brunelle P
J Pain Symptom Manage; 2003 Feb; 25(2):185-90. PubMed ID: 12590034
[TBL] [Abstract][Full Text] [Related]
6. Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour.
Teng J; Abell S; Hicks RJ; Hofman MS; Sachithanandan N; McKelvie P; MacIsaac RJ
Clin Endocrinol (Oxf); 2014 Dec; 81(6):940-2. PubMed ID: 24890549
[No Abstract] [Full Text] [Related]
7. Malignancy associated hypercalcaemia-responsiveness to IV bisphosphonates and prognosis in a palliative population.
Mallik S; Mallik G; Macabulos ST; Dorigo A
Support Care Cancer; 2016 Apr; 24(4):1771-7. PubMed ID: 26441077
[TBL] [Abstract][Full Text] [Related]
8. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
9. Tumour-induced hypercalcaemia, resistant to systemic anti-hypercalcaemic and chemo-endocrine treatments, but responding to radiotherapy in a breast cancer patient.
Nesković-Konstantinović Z; Susnjar S; Vasović S; Borojević N; Mitrović L; Radosević-Jelić L; Radulović S
Acta Oncol; 1996; 35(4):501-3. PubMed ID: 8695173
[No Abstract] [Full Text] [Related]
10. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
11. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Body JJ; Dumon JC
Ann Oncol; 1994 Apr; 5(4):359-63. PubMed ID: 8075034
[TBL] [Abstract][Full Text] [Related]
12. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
Kutluk T; Akyüz C; Yalçin B; Varan A; Büyükpamuküçu M
Med Pediatr Oncol; 1998 Jul; 31(1):39. PubMed ID: 9607431
[No Abstract] [Full Text] [Related]
13. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
14. [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin].
Kusama M; Kaise H; Nakayama S; Ota D; Aoki T; Koyanagi Y; Matsunaga T; Nakamura Y
Gan To Kagaku Ryoho; 2000 May; 27(5):763-6. PubMed ID: 10832449
[TBL] [Abstract][Full Text] [Related]
15. Hypercalcemia of malignancy remains a clinically relevant problem.
Van Poznak C
Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
[No Abstract] [Full Text] [Related]
16. One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancy.
Sawyer N; Newstead C; Drummond A; Newland A; Cunningham J
Clin Lab Haematol; 1989; 11(3):179-84. PubMed ID: 2591149
[TBL] [Abstract][Full Text] [Related]
17. Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.
Mishra A; Wong L; Jonklaas J
Endocrine; 2001 Mar; 14(2):159-64. PubMed ID: 11394632
[TBL] [Abstract][Full Text] [Related]
18. Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.
Cantwell B; Harris AL
Lancet; 1986 Jan; 1(8473):165-6. PubMed ID: 2867388
[No Abstract] [Full Text] [Related]
19. Evaluation and treatment of hypercalcemia.
Mundy GR
Hosp Pract (Off Ed); 1994 Jun; 29(6):79-84; discussion 84-6. PubMed ID: 8207113
[No Abstract] [Full Text] [Related]
20. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy.
McIntyre HD; Cameron DP; Urquhart SM; Davies WE
Postgrad Med J; 1989 Apr; 65(762):244-6. PubMed ID: 2594602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
